Abstract：
OBJECTIVE: Understanding the dynamics of serum Mac-2 binding protein glycosylation isomer (M2BPGi) remains pivotal for hepatitis C virus (HCV) patients\' post-sustained virologic response (SVR12) through direct-acting antivirals (DAAs).
METHODS: We compared areas under receiver operating characteristic curves (AUROCs) of M2BPGi, FIB-4, and APRI and assess M2BPGi cutoff levels in predicting fibrosis stages of ≥F3 and F4 utilizing transient elastography in 638 patients. Variations in M2BPGi levels from pretreatment to SVR12 and their association with pretreatment alanine transaminase (ALT) levels and fibrosis stage were investigated.
RESULTS: The AUROCs of M2BPGi were comparable to FIB-4 in predicting ≥F3 (0.914 vs 0.902, P = 0.48) and F4 (0.947 vs 0.915, P = 0.05) but were superior to APRI in predicting ≥F3 (0.914 vs 0.851, P = 0.001) and F4 (0.947 vs 0.857, P < 0.001). Using M2BPGi cutoff values of 2.83 and 3.98, fibrosis stages of ≥F3 and F4 were confirmed with a positive likelihood ratio ≥10. The median M2BPGi change was -0.55. Patients with ALT levels ≥5 times ULN or ≥F3 demonstrated more pronounced median decreases in M2BPGi level compared to those with ALT levels 2-5 times ULN and <2 times ULN (-0.97 vs -0.68 and -0.44; P < 0.001) or with < F3 (-1.52 vs -0.44; P < 0.001).
CONCLUSIONS: Serum M2BPGi is a reliable marker for advanced hepatic fibrosis. Following viral clearance, there is a notable M2BPGi decrease, with the extent of reduction influenced by ALT levels and fibrosis stage.
METHODS: We compared areas under receiver operating characteristic curves (AUROCs) of M2BPGi, FIB-4, and APRI and assess M2BPGi cutoff levels in predicting fibrosis stages of ≥F3 and F4 utilizing transient elastography in 638 patients. Variations in M2BPGi levels from pretreatment to SVR12 and their association with pretreatment alanine transaminase (ALT) levels and fibrosis stage were investigated.
RESULTS: The AUROCs of M2BPGi were comparable to FIB-4 in predicting ≥F3 (0.914 vs 0.902, P = 0.48) and F4 (0.947 vs 0.915, P = 0.05) but were superior to APRI in predicting ≥F3 (0.914 vs 0.851, P = 0.001) and F4 (0.947 vs 0.857, P < 0.001). Using M2BPGi cutoff values of 2.83 and 3.98, fibrosis stages of ≥F3 and F4 were confirmed with a positive likelihood ratio ≥10. The median M2BPGi change was -0.55. Patients with ALT levels ≥5 times ULN or ≥F3 demonstrated more pronounced median decreases in M2BPGi level compared to those with ALT levels 2-5 times ULN and <2 times ULN (-0.97 vs -0.68 and -0.44; P < 0.001) or with < F3 (-1.52 vs -0.44; P < 0.001).
CONCLUSIONS: Serum M2BPGi is a reliable marker for advanced hepatic fibrosis. Following viral clearance, there is a notable M2BPGi decrease, with the extent of reduction influenced by ALT levels and fibrosis stage.
摘要：
目的：了解血清Mac-2结合蛋白糖基化异构体（M2BPGi）的动力学对于丙型肝炎病毒（HCV）患者的持续病毒学应答（SVR12）通过直接作用抗病毒药物（DAA）仍然至关重要。
方法：我们比较了M2BPGi，FIB-4和APRI和评估M2BPGi截止水平在预测纤维化分期≥F3和F4利用瞬时弹性成像638例患者。研究了从预处理到SVR12的M2BPGi水平变化及其与预处理丙氨酸转氨酶（ALT）水平和纤维化阶段的关联。
结果：M2BPGi的AUROC在预测≥F3（0.914vs0.902，P=0.48）和F4（0.947vs0.915，P=0.05）方面与FIB-4相当，但在预测≥F3（0.914vs0.851，P=0.001）和F4（0.947vs0.857，P<0.001）方面优于APRI。使用2.83和3.98的M2BPGi截止值，证实纤维化分期≥F3和F4，阳性似然比≥10。M2BPGi变化中位数为-0.55。与ALT水平2-5倍ULN和<2倍ULN（-0.97vs-0.68和-0.44;P<0.001）或结论：血清M2BPGi是晚期肝纤维化的可靠标志物。病毒清除后，M2BPGi有显著下降，与ALT水平和纤维化阶段影响的降低程度。
方法：我们比较了M2BPGi，FIB-4和APRI和评估M2BPGi截止水平在预测纤维化分期≥F3和F4利用瞬时弹性成像638例患者。研究了从预处理到SVR12的M2BPGi水平变化及其与预处理丙氨酸转氨酶（ALT）水平和纤维化阶段的关联。
结果：M2BPGi的AUROC在预测≥F3（0.914vs0.902，P=0.48）和F4（0.947vs0.915，P=0.05）方面与FIB-4相当，但在预测≥F3（0.914vs0.851，P=0.001）和F4（0.947vs0.857，P<0.001）方面优于APRI。使用2.83和3.98的M2BPGi截止值，证实纤维化分期≥F3和F4，阳性似然比≥10。M2BPGi变化中位数为-0.55。与ALT水平2-5倍ULN和<2倍ULN（-0.97vs-0.68和-0.44;P<0.001）或
